Associated Papers
The Mutational Spectrum of Pre- and Post-Neoadjuvant Chemotherapy Triple-Negative Breast Cancers.
Aguilar-Mahecha A et al.
Genes, 2023
38254917 (PubMed )
Supplement: genes-15-00027-s001.zip › Aguilar-Mahecha_et_al_SupplTables_Finalv2.xlsx › Supp_Table_S10
Novel, clinically relevant genomic patterns identified by comprehensive genomic profiling in ATRX-deficient IDH-wildtype adult high-grade gliomas.
Bedics G et al.
Scientific Reports, 2023
37891325 (PubMed )
Supplement: 41598_2023_45786_MOESM2_ESM.xlsx › Table_S2
Analyzing aggregation propensities of clinically relevant PTEN mutants: a new culprit in pathogenesis of cancer and other PTENopathies.
Palumbo E et al.
Journal of Biomolecular Structure & Dynamics, 2020
Implementing a comprehensive translational oncology platform: from molecular testing to actionability.
Mitri ZI et al.
Journal of Translational Medicine, 2018
30551737 (PubMed )
Supplement: 12967_2018_1733_MOESM1_ESM.pdf
Clonal architectures and driver mutations in metastatic melanomas.
Ding L et al.
Plos One, 2014
25393105 (PubMed )
Supplement: pone.0111153.s002.zip › File_S2 › Table_S11.xls › Supp_Table_11
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors.
Mendes-Pereira AM et al.
Embo Molecular Medicine, 2009
20049735 (PubMed )
Supplement: emmm0001-0315-SD1.pdf
Select a paper to view details